FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

TYSON TIMOTHY		 2. Issuer Name and Ticker or Trading Symbol

Syros Pharmaceuticals, Inc. [ SYRS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

35 CAMBRIDGEPARK DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)

9/16/2022
(Street)

CAMBRIDGE, MA 02140		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

9/19/2022 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/16/2022  A  8000 A$0.00 8000 D  
Common Stock 9/16/2022  A  257 A (1)8257 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $7.349 9/16/2022  A   12000     (2)9/15/2032 Common Stock 12000 $0.00 12000 D  
Stock Option (right to buy) $93.56 9/16/2022  A   2232     (3)11/21/2022 Common Stock 2232  (3)2232 D  
Stock Option (right to buy) $199.68 9/16/2022  A   1094     (4)5/9/2026 Common Stock 1094  (4)1094 D  
Stock Option (right to buy) $66.18 9/16/2022  A   3286     (5)5/24/2028 Common Stock 3286  (5)3286 D  
Stock Option (right to buy) $53.17 9/16/2022  A   2191     (6)8/26/2028 Common Stock 2191  (6)2191 D  
Stock Option (right to buy) $26.93 9/16/2022  A   2191     (7)8/22/2029 Common Stock 2191  (7)2191 D  
Stock Option (right to buy) $27.84 9/16/2022  A   2848     (8)8/19/2030 Common Stock 2848  (8)2848 D  
Stock Option (right to buy) $25.10 9/16/2022  A   3856     (9)8/23/2031 Common Stock 3856  (9)3856 D  
Stock Option (right to buy) $7.07 9/16/2022  A   3856     (10)8/23/2032 Common Stock 3856  (10)3856 D  
Explanation of Responses:
(1) Acquired pursuant to the merger agreement between the issuer and Tyme Technologies, Inc. ("Tyme") in exchange for 5,865 shares of Tyme common stock having a market value of $0.3086 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
(2) The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
(3) This option is fully vested and replaced an option to purchase 50,058 shares of Tyme common stock at an exercise price of $4.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(4) This option is fully vested and replaced an option to purchase 25,000 shares of Tyme common stock at an exercise price of $8.75 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(5) This option is fully vested and replaced an option to purchase 75,000 shares of Tyme common stock at an exercise price of $2.90 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(6) This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $2.33 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(7) This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $1.18 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(8) This option is fully vested and replaced an option to purchase 65,000 shares of Tyme common stock at an exercise price of $1.22 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(9) This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $1.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
(10) This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $0.31 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.

Remarks:
This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct the inadvertent omission of the Reporting Person's beneficial ownership of certain securities issued in connection with the closing of the merger with Tyme on September 16, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
TYSON TIMOTHY
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140		X
Signatures
/s/ Todd Rosenthal, as attorney-in-fact4/20/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.